Research programme: adoptive T-cell therapy - Medigene

Drug Profile

Research programme: adoptive T-cell therapy - Medigene

Alternative Names: Immunotherapy-Medigene Immunotherapies; TCR-modified T-cells-Medigene Immunotherapies

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Helmholtz Zentrum Munchen; Max Delbruck Center for Molecular Medicine
  • Developer Medigene Immunotherapies
  • Class Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 May 2016 Medigene plans three trials for Cancer in 2016/2017/2018
  • 28 Jan 2016 Medigene in-licenses NTAmer technology from the University of Lausanne
  • 07 Nov 2014 Trianta Immunotherapies is now called Medigene Immunotherapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top